UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies

European journal of cancer (1990), 2012-12, Vol.48 (18), p.3319-3327

2012

Volltextzugriff (PDF)

2346 Impact of nab-paclitaxel (nab-P) plus gemcitabine (G) vs gemcitabine alone on Karnofsky performance status (KPS) in metastatic pancreatic cancer patients with good or poor performance status at baseline: A post-hoc analysis of the MPACT trial

European journal of cancer (1990), 2015-09, Vol.51, p.S450-S450

2015

Volltextzugriff (PDF)

617 Pharmacokinetic Study of Enzastaurin in Cancer Patients with Varying Degrees of Hepatic Dysfunction

European journal of cancer (1990), 2012-11, Vol.48, p.190-190

2012

Volltextzugriff (PDF)

Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group trial

The Year book of oncology, 2012-01, Vol.2012, p.141-142

Chiorean, E.G.

2012

Volltextzugriff (PDF)

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

The Year book of oncology, 2012-01, Vol.2012, p.138-139

Chiorean, E.G.

2012

Volltextzugriff (PDF)

Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial

The Year book of oncology, 2012-01, Vol.2012, p.136-138

Chiorean, E.G.

2012

Volltextzugriff (PDF)

A Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for T2N0 Rectal Cancer: Preliminary Results of the ACOSOG Z6041 Trial

The Year book of oncology, 2012-01, Vol.2012, p.142-144

Chiorean, E.G.

2012

Volltextzugriff (PDF)

Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors

Annals of oncology, 2015-06, Vol.26 (6), p.1230-1237

2015

Volltextzugriff (PDF)

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

The Year book of oncology, 2011-01, Vol.2011, p.197-199

Chiorean, E.G.

2011

Volltextzugriff (PDF)

A Phase 2 Trial of Gemcitabine, 5-Fluorouracil, and Radiation Therapy in Locally Advanced Nonmetastatic Pancreatic Adenocarcinoma: Cancer and Leukemia Group B (CALGB) 80003

The Year book of oncology, 2011-01, Vol.2011, p.189-190

Chiorean, E.G.

2011

Volltextzugriff (PDF)

DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy

The Year book of oncology, 2011-01, Vol.2011, p.195-197

Chiorean, E.G.

2011

Volltextzugriff (PDF)

DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy

Year book of medicine, 2011-01, Vol.2011, p.139-141

Chiorean, E.G.

2011

Volltextzugriff (PDF)

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Year book of medicine, 2011-01, Vol.2011, p.133-135

Chiorean, E.G.

2011

Volltextzugriff (PDF)

Clinical Outcomes and Immunotoxicity in People with HIV (PWH) after Definitive Chemoradiation (CRT) for Anal Squamous Cell Carcinoma

International journal of radiation oncology, biology, physics, 2023-10, Vol.117 (2), p.e282-e283

2023

Volltextzugriff (PDF)

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

Annals of oncology, 2016-04, Vol.27 (4), p.654-660

2016

Volltextzugriff (PDF)

114P Prospective longitudinal tumor-informed ctDNA in resectable biliary tract cancers

Annals of oncology, 2023-10, Vol.34, p.S225-S225

2023

Volltextzugriff (PDF)

Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine (nab-P/G) vs FOLFIRINOX (FFX) in patients (pts) with advanced pancreatic cancer (aPC)

Annals of oncology, 2018-10, Vol.29, p.viii245-viii246

2018

Volltextzugriff (PDF)

493P Pembrolizumab (pembro) plus mFOLFOX7 or FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC): Updated results from KEYNOTE-651 cohorts B and D

Annals of oncology, 2020-09, Vol.31, p.S450-S450

2020

Volltextzugriff (PDF)

564P Updated results of a phase I study of Felezonexor (SL-801), a novel XPO-1 reversible inhibitor, in patients with relapsed/refractory solid tumours

Annals of oncology, 2020-09, Vol.31, p.S485-S486

2020

Volltextzugriff (PDF)

Interim results from a phase I trial of SL-801: A novel XPO-1 inhibitor, in patients with advanced solid tumors

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii140

2018

Volltextzugriff (PDF)

Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline

Annals of oncology, 2016-08, Vol.27 (8), p.1647-1648

2016

Volltextzugriff (PDF)

1226 Multi-arm Phase IB study of TH-302 in combination with gemcitabine, docetaxel or pemetrexed

European journal of cancer supplements, 2009, Vol.7 (2), p.128-128

2009

Volltextzugriff (PDF)

Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors

Annals of oncology, 2012-04, Vol.23 (4), p.1037-1044

2012

Volltextzugriff (PDF)

412 POSTER A first-in-man phase I study of TH-302, a hypoxia-activated cytotoxic prodrug

European journal of cancer supplements, 2008, Vol.6 (12), p.129-130

2008

Volltextzugriff (PDF)

41 POSTER DCE-MRI endpoints reveal decreased tumor vascularity in patients with liver metastases: a Phase I dose escalating study with IMC-1121B

European journal of cancer supplements, 2008, Vol.6 (12), p.16-16

2008

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(17)
Mit Volltextzugriff
(17)

Publikationsform

Artikel
(26)

Sprache

Englisch
(26)

Erscheinungsjahr

n.n

Kollektion

EZB Electronic Journals Library
(13)
Ovid
(10)
Ingenta
(7)
Elsevier ScienceDirect Journals Complete
(7)
MEDLINE
(5)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(4)
IngentaConnect Journals
(4)

2 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

1 weiteren anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies

2346 Impact of nab-paclitaxel (nab-P) plus gemcitabine (G) vs gemcitabine alone on Karnofsky performance status (KPS) in metastatic pancreatic cancer patients with good or poor performance status at baseline: A post-hoc analysis of the MPACT trial

617 Pharmacokinetic Study of Enzastaurin in Cancer Patients with Varying Degrees of Hepatic Dysfunction

Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group trial

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial

A Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for T2N0 Rectal Cancer: Preliminary Results of the ACOSOG Z6041 Trial

Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

A Phase 2 Trial of Gemcitabine, 5-Fluorouracil, and Radiation Therapy in Locally Advanced Nonmetastatic Pancreatic Adenocarcinoma: Cancer and Leukemia Group B (CALGB) 80003

DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy

DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Clinical Outcomes and Immunotoxicity in People with HIV (PWH) after Definitive Chemoradiation (CRT) for Anal Squamous Cell Carcinoma

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

114P Prospective longitudinal tumor-informed ctDNA in resectable biliary tract cancers

Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine (nab-P/G) vs FOLFIRINOX (FFX) in patients (pts) with advanced pancreatic cancer (aPC)

493P Pembrolizumab (pembro) plus mFOLFOX7 or FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC): Updated results from KEYNOTE-651 cohorts B and D

564P Updated results of a phase I study of Felezonexor (SL-801), a novel XPO-1 reversible inhibitor, in patients with relapsed/refractory solid tumours

Interim results from a phase I trial of SL-801: A novel XPO-1 inhibitor, in patients with advanced solid tumors

Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline

1226 Multi-arm Phase IB study of TH-302 in combination with gemcitabine, docetaxel or pemetrexed

Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors

412 POSTER A first-in-man phase I study of TH-302, a hypoxia-activated cytotoxic prodrug

41 POSTER DCE-MRI endpoints reveal decreased tumor vascularity in patients with liver metastases: a Phase I dose escalating study with IMC-1121B

Suchergebnisse filtern